

HELGA B. SALVESEN was born in Oslo, Norway, in 1963, and grew up in the city of Bergen, earning her M.D. degree at the University of Bergen in 1989, followed by her Ph.D. in 2000. Dr. Salvesen was appointed a professor in the Department of Clinical Science at the University of Bergen in 2003, and also held an appointment in the Department of Gynecology and Obstetrics at Haukeland

University Hospital. She lived in Boston twice as a visiting professor, at the Dana-Farber Cancer Institute in 2004–5, funded by a Fulbright Foundation award, and the Broad Institute of Harvard and MIT in 2012–13. Dr. Salvesen was a member of the TCGA disease working groups for endometrial cancer, cervical cancer, and uterine carcinosarcoma, and in 2015, she was elected to the Norwegian Academy of Science and Letters.

Dr. Salvesen was thoughtful and generous and loved by her peers. She authored over 150 publications, including several prominent papers on endometrial and cervical cancer genomics with collaborators from Bergen and Boston. She is co-senior author on one such paper just published posthumously at *Nature Genetics*, entitled "The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis".

Dr. Salvesen is survived by her husband, Dr. Pål Njølstad, and four sons.



# Helga Salvesen Memorial Symposium on Endometrial Cancer

### Monday, October 24, 2016 8:30 a.m. – 5:30 p.m.

Broad Institute of MIT and Harvard 415 Main Street • Cambridge, MA







### Helga Salvesen Memorial Symposium on Endometrial Cancer

#### 8:00 a.m. Registration/Breakfast

## 8:30 a.m. SESSION 1: INTRODUCTION AND CLINICAL TRANSLATION

Rameen Beroukhim, Session Chair Yellowstone | Second Floor, Room 2001

Welcome and Introduction Todd Golub

Helga Salvesen Memorial Symposium introductory remarks Rameen Beroukhim

Personal reflections on Helga Salvesen's life as scientist, spouse and mother Pål Njølstad

**Directions in endometrial cancer therapeutics** *Ursula Matulonis* 

**Endometrial Cancer: Is there a role for immunotherapy?**" *Panos Konstantinopolous* 

Unmet needs in the management of endometrial cancer *Doug Levine* 

#### 10:15 a.m. Coffee Break

#### 10:45 a.m. SESSION 2: ENDOMETRIAL CANCER GENOMICS AND BIOLOGY

Heidi Greulich, Session Chair Yellowstone | Second Floor, Room 2001

**Endometrial carcinogenesis** *George Mutter* 

**Patient derived uterine cancer xenografts** *Frederic Amant* Dentist Olaf and Mrs. Aase legacy lecture

The mutational spectrum of clear cell endometrial carcinomas Daphne Bell MAX mutations in endometrial cancer: discovery, clinicopathologic significance, and functional consequences of the recurrent p.His28Arg mutation *Paul Goodfellow* 

Biological insights from genome analysis of breast and cervical adenocarcinomas *Amit Dutt* 

1:00 p.m. Lunch Break Monadnock | Second Floor, Room 2040

2:30 p.m. SESSION 3: CONTINUING HELGA'S LEGACY Erling Hoivik, Session Chair Auditorium | First Floorx

> **Imaging biomarkers in endometrial cancer** *Ingfrid Salvesen Haldorsen*

The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis *Erling Hoivik and Will Gibson* 

Somatic genomic slterations in "endometrial-like" cervical carcinomas Akin Ojesina

Tumor-vascular interactions in endometrial and breast cancer Lars Akslen

Helga Salvesen: friend and mentor for Bergen Gynecologic Cancer Research Group Jone Trovik

Thoughts on Helga and her legacy Levi Garraway, Gad Getz, Matthew Meyerson, and William Sellers

**Closing Remarks** Rameen Beroukhim

5:00 p.m. Reception in Broad Lobby